Barclays
MPLT

Barclays’s MapLight Therapeutics MPLT Stock Holding History

Barclays’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$465K Buy
12,975
+7,186
+124% +$207K ﹤0.01% 3272
2026
Q1 		$118K Sell
5,789
-20,626
-78% -$369K ﹤0.01% 3961
2025
Q4 		$464K Buy
+26,415
New +$443K ﹤0.01% 3895

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Barclays's MPLT Position: Q2 2026 in Review

Barclays increased its MapLight Therapeutics (MPLT) stake by 124% in Q2 2026, buying an estimated $207K and bringing the position to 12,975 shares worth $465K. The position accounts for ﹤0.01% of the portfolio, ranked #3272.

Barclays first reported a position in MPLT in Q4 2025 and has held it in 3 quarters since. 100 funds tracked by Wall St. Rank hold MPLT as of Q2 2026.

  • Barclays held 12,975 shares of MapLight Therapeutics worth $465K as of Q2 2026.
  • Barclays bought 7,186 MapLight Therapeutics shares in Q2 2026, an estimated $207K.
  • MapLight Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3272 holding.
  • Barclays first reported a position in MapLight Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 100 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.